LENALIDOMIDE EG 5 mg, hard capsule 21 capsules
Active ingredients: LÉNALIDOMIDE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule21 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LENALIDOMIDE EG 5 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 3 plaquettes PVC polychlortrifluoroéthylène aluminium de 7 gélules
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 7 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64848925CIP73021425CIP133400930214251Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉNALIDOMIDEgélule | 5 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: LENALIDOMIDE 5 mg - LENALIDOMIDE (CHLORHYDRATE DE) HYDRATE équivalant à LENALIDOMIDE 5 mg - REVLIMID 5 mg, gélule